ReviewDiscover oncology2026
Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The HIF-1α-Th17/Treg axis in pediatric infectious mononucleosis: a clinical investigation of metabolic-immune dysregulation.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Epstein-Barr Virus (EBV), a herpesvirus closely linked to multiple types of lymphoma, promotes tumorigenesis through various mechanisms, including inducing genomic instability, reprogramming key signaling pathways, and evading host immune surveillance. In Burkitt Lymphoma (BL), aberrant activation of the MYC gene is recognized as a pivotal driver event, while recent reports indicate that EBV nuclear antigen 1 (EBNA1) and latent membrane protein 1 (LMP1) significantly enhance tumor cell proliferation and immune evasion by regulating host chromatin structure and antigen presentation processes. In Diffuse Large B cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL), EBV latent proteins such as LMP1 and latent membrane protein 2A (LMP2A) activate the NF-κB and JAK/STAT signaling pathways, reshaping the tumor microenvironment, enhancing anti-apoptotic survival signals, and promoting immune suppression. Furthermore, EBV-encoded microRNAs and long non-coding RNAs (lncRNAs) further modulate host gene expression and metabolic pathways, increasing tumor heterogeneity and therapeutic resistance. Despite advances in targeting MYC, the PI3K/AKT pathway, and immune checkpoints, issues such as resistance, high toxicity, and the complexity of the tumor microenvironment limit their clinical applicability. Emerging immunotherapies, including CAR-T cell therapy, EBV-specific T-cell therapy, and epigenetic targeting, show significant potential in optimizing the immune microenvironment and overcoming therapeutic resistance. However, the molecular heterogeneity of EBV-associated lymphomas poses greater challenges for precision medicine strategies. Future research needs to integrate multi-omics data to elucidate the complex molecular interactions between EBV and its host, laying the groundwork for the development of multi-targeted combinatorial therapies and innovative diagnostic and therapeutic approaches. This review systematically summarizes the core mechanisms by which EBV contributes to lymphoma pathogenesis and evaluates the breakthroughs and challenges of current therapeutic strategies. It also outlines the future directions of precision medicine, based on multi-disciplinary integration, to enhance the understanding of the molecular pathology of EBV-associated lymphomas and optimize personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.